Cinnamaldehyde Impacts Key Cellular Signaling Pathways for Induction of Programmed Cell Death in High-grade and Low-grade Human Glioma Cells

Overview

Journal BMC Res Notes

Publisher Biomed Central

Date 2025 Jan 20

PMID 39833890

Authors

Yoo Na Kim

Ketki Patil

S Balakrishna Pai

Affiliations

Soon will be listed here.

Abstract

Objective: Primary tumors of the brain and a large percent of malignant brain tumors are gliomas. Gliomas comprise high-grade gliomas like glioblastoma multiforme (GBMs), many of which have mutation in the tumor suppressor p53 gene and low-grade gliomas (LGGs). LGGs can progress to GBMs due to various factors. The available treatment options for GBMs and LGGs include surgical resection, radiation and chemotherapy. The chemotherapeutic drug available in the clinic is temozolomide (TMZ). However, TMZ can cause damage to DNA if taken for prolonged period. This warrants the discovery of drugs that would potentially elicit less adverse side effects while maintaining anticancer activity. To this end, we evaluated the impact of cinnamaldehyde (CA), a single, purified component of the natural product cinnamon.

Results: The elucidation of the mechanism of action revealed the impact of CA on reactive oxygen species (ROS) levels. Moreover, its effect on the extrinsic programmed cell death pathway resulted in the increase of apoptotic cell populations, invoking multicaspase. Notably, the cell survival/death pivotal molecule Bcl-2 was impacted. These effects were observed in both the types of brain tumor cells studied: GBMs, represented by U251 cells (p53 mutated cell line) and LGGs represented by H4 cells. Results from the current study suggest potential for CA as a therapeutic option as it is expected to have fewer adverse side effects due to it being a component of a natural product and possibly deter the progression of LGGs to GBMs.

References

Lin L, Tai C, Chang S, Chen J, Wu S, Lin C . Cinnamaldehyde-induced apoptosis in human hepatoma PLC/PRF/5 cells involves the mitochondrial death pathway and is sensitive to inhibition by cyclosporin A and z-VAD-fmk. Anticancer Agents Med Chem. 2013; 13(10):1565-74. DOI: 10.2174/18715206113139990144. View

Srivastava S, Patil K, Thompson E, Nakhai S, Kim Y, Haynes C . Disruption of Glioblastoma Multiforme Cell Circuits with Cinnamaldehyde Highlights Potential Targets with Implications for Novel Therapeutic Strategies. Cells. 2023; 12(9). PMC: 10177046. DOI: 10.3390/cells12091277. View

Johnson D, Patrick ONeill B . Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2011; 107(2):359-64. DOI: 10.1007/s11060-011-0749-4. View

Oberheim Bush N, Chang S . Treatment Strategies for Low-Grade Glioma in Adults. J Oncol Pract. 2016; 12(12):1235-1241. DOI: 10.1200/JOP.2016.018622. View

Furnari F, Fenton T, Bachoo R, Mukasa A, Stommel J, Stegh A . Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007; 21(21):2683-710. DOI: 10.1101/gad.1596707. View

Deng L, Feng Z, Deng H, Jiang Y, Song K, Shi Y . Rational Design of Nanoparticles to Overcome Poor Tumor Penetration and Hypoxia-Induced Chemotherapy Resistance: Combination of Optimizing Size and Self-Inducing High Level of Reactive Oxygen Species. ACS Appl Mater Interfaces. 2019; 11(35):31743-31754. DOI: 10.1021/acsami.9b12129. View

Liu Y, Liu H, Wang L, Wang Y, Zhang C, Wang C . Amplification of oxidative stress intracellular ROS production and antioxidant consumption by two natural drug-encapsulated nanoagents for efficient anticancer therapy. Nanoscale Adv. 2022; 2(9):3872-3881. PMC: 9419310. DOI: 10.1039/d0na00301h. View

Ahn C, Park J, Kim J, Ahn K, Kim Y, Jeong M . Cinnamaldehyde and Hyperthermia Co-Treatment Synergistically Induces ROS-Mediated Apoptosis in ACHN Renal Cell Carcinoma Cells. Biomedicines. 2020; 8(9). PMC: 7555957. DOI: 10.3390/biomedicines8090357. View

Forst D, Nahed B, Loeffler J, Batchelor T . Low-grade gliomas. Oncologist. 2014; 19(4):403-13. PMC: 3983820. DOI: 10.1634/theoncologist.2013-0345. View

10.

Claus E, Walsh K, Wiencke J, Molinaro A, Wiemels J, Schildkraut J . Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus. 2015; 38(1):E6. PMC: 4361022. DOI: 10.3171/2014.10.FOCUS12367. View

11.

He W, Li X, Morsch M, Ismail M, Liu Y, Rehman F . Brain-Targeted Codelivery of Bcl-2/Bcl-xl and Mcl-1 Inhibitors by Biomimetic Nanoparticles for Orthotopic Glioblastoma Therapy. ACS Nano. 2022; 16(4):6293-6308. DOI: 10.1021/acsnano.2c00320. View

12.

Gersey Z, Rodriguez G, Barbarite E, Sanchez A, Walters W, Ohaeto K . Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species. BMC Cancer. 2017; 17(1):99. PMC: 5292151. DOI: 10.1186/s12885-017-3058-2. View

13.

Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister S . Glioma. Nat Rev Dis Primers. 2016; 1:15017. DOI: 10.1038/nrdp.2015.17. View

14.

Dong J, Wang F, Gao X, Zhao H, Zhang J, Wang N . Integrated analysis of genome-wide DNA methylation and cancer-associated fibroblasts identified prognostic biomarkers and immune checkpoint blockade in lower grade gliomas. Front Oncol. 2023; 12:977251. PMC: 9885112. DOI: 10.3389/fonc.2022.977251. View

15.

England B, Huang T, Karsy M . Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol. 2013; 34(4):2063-74. DOI: 10.1007/s13277-013-0871-3. View

16.

Chang C, Shen C, Su H, Chen C . Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation. J Neurooncol. 2011; 105(3):507-22. DOI: 10.1007/s11060-011-0632-3. View

17.

Teng C, Zhu Y, Li Y, Dai L, Pan Z, Wanggou S . Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy. Front Immunol. 2022; 13:899710. PMC: 9168984. DOI: 10.3389/fimmu.2022.899710. View

18.

Jia B, Zheng X, Wu M, Tian X, Song X, Liu Y . Increased Reactive Oxygen Species and Distinct Oxidative Damage in Resveratrol-suppressed Glioblastoma Cells. J Cancer. 2021; 12(1):141-149. PMC: 7738840. DOI: 10.7150/jca.45489. View

19.

Chantaravisoot N, Wongkongkathep P, Kalpongnukul N, Pacharakullanon N, Kaewsapsak P, Ariyachet C . mTORC2 interactome and localization determine aggressiveness of high-grade glioma cells through association with gelsolin. Sci Rep. 2023; 13(1):7037. PMC: 10148843. DOI: 10.1038/s41598-023-33872-y. View

20.

Davis M . Epidemiology and Overview of Gliomas. Semin Oncol Nurs. 2018; 34(5):420-429. DOI: 10.1016/j.soncn.2018.10.001. View